Cargando…
Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019
AIM: To report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019. METHODS: We used the data of the Global Burden of Disease (GBD) Study 2019 to report number an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915203/ https://www.ncbi.nlm.nih.gov/pubmed/35282442 http://dx.doi.org/10.3389/fendo.2022.838027 |
_version_ | 1784667962719862784 |
---|---|
author | Safiri, Saeid Karamzad, Nahid Kaufman, Jay S. Bell, Arielle Wilder Nejadghaderi, Seyed Aria Sullman, Mark J. M. Moradi-Lakeh, Maziar Collins, Gary Kolahi, Ali-Asghar |
author_facet | Safiri, Saeid Karamzad, Nahid Kaufman, Jay S. Bell, Arielle Wilder Nejadghaderi, Seyed Aria Sullman, Mark J. M. Moradi-Lakeh, Maziar Collins, Gary Kolahi, Ali-Asghar |
author_sort | Safiri, Saeid |
collection | PubMed |
description | AIM: To report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019. METHODS: We used the data of the Global Burden of Disease (GBD) Study 2019 to report number and age-standardised rates per 100 000 population of type 2 diabetes. Estimates were reported with 95% uncertainty intervals (UIs). RESULTS: In 2019, the global age-standardised point prevalence and death rates for type 2 diabetes were 5282.9 and 18.5 per 100 000, an increase of 49% and 10.8%, respectively, since 1990. Moreover, the global age-standardised DALY rate in 2019 was 801.5 per 100 000, an increase of 27.6% since 1990. In 2019, the global point prevalence of type 2 diabetes was slightly higher in males and increased with age up to the 75-79 age group, decreasing across the remaining age groups. American Samoa [19876.8] had the highest age-standardised point prevalence rates of type 2 diabetes in 2019. Generally, the burden of type 2 diabetes decreased with increasing SDI (Socio-demographic Index). Globally, high body mass index [51.9%], ambient particulate matter pollution [13.6%] and smoking [9.9%] had the three highest proportions of attributable DALYs. CONCLUSION: Low and middle-income countries have the highest burden and greater investment in type 2 diabetes prevention is needed. In addition, accurate data on type 2 diabetes needs to be collected by the health systems of all countries to allow better monitoring and evaluation of population-level interventions. |
format | Online Article Text |
id | pubmed-8915203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89152032022-03-12 Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 Safiri, Saeid Karamzad, Nahid Kaufman, Jay S. Bell, Arielle Wilder Nejadghaderi, Seyed Aria Sullman, Mark J. M. Moradi-Lakeh, Maziar Collins, Gary Kolahi, Ali-Asghar Front Endocrinol (Lausanne) Endocrinology AIM: To report the point prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories during the period 1990-2019. METHODS: We used the data of the Global Burden of Disease (GBD) Study 2019 to report number and age-standardised rates per 100 000 population of type 2 diabetes. Estimates were reported with 95% uncertainty intervals (UIs). RESULTS: In 2019, the global age-standardised point prevalence and death rates for type 2 diabetes were 5282.9 and 18.5 per 100 000, an increase of 49% and 10.8%, respectively, since 1990. Moreover, the global age-standardised DALY rate in 2019 was 801.5 per 100 000, an increase of 27.6% since 1990. In 2019, the global point prevalence of type 2 diabetes was slightly higher in males and increased with age up to the 75-79 age group, decreasing across the remaining age groups. American Samoa [19876.8] had the highest age-standardised point prevalence rates of type 2 diabetes in 2019. Generally, the burden of type 2 diabetes decreased with increasing SDI (Socio-demographic Index). Globally, high body mass index [51.9%], ambient particulate matter pollution [13.6%] and smoking [9.9%] had the three highest proportions of attributable DALYs. CONCLUSION: Low and middle-income countries have the highest burden and greater investment in type 2 diabetes prevention is needed. In addition, accurate data on type 2 diabetes needs to be collected by the health systems of all countries to allow better monitoring and evaluation of population-level interventions. Frontiers Media S.A. 2022-02-25 /pmc/articles/PMC8915203/ /pubmed/35282442 http://dx.doi.org/10.3389/fendo.2022.838027 Text en Copyright © 2022 Safiri, Karamzad, Kaufman, Bell, Nejadghaderi, Sullman, Moradi-Lakeh, Collins and Kolahi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Safiri, Saeid Karamzad, Nahid Kaufman, Jay S. Bell, Arielle Wilder Nejadghaderi, Seyed Aria Sullman, Mark J. M. Moradi-Lakeh, Maziar Collins, Gary Kolahi, Ali-Asghar Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 |
title | Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 |
title_full | Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 |
title_fullStr | Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 |
title_full_unstemmed | Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 |
title_short | Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019 |
title_sort | prevalence, deaths and disability-adjusted-life-years (dalys) due to type 2 diabetes and its attributable risk factors in 204 countries and territories, 1990-2019: results from the global burden of disease study 2019 |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915203/ https://www.ncbi.nlm.nih.gov/pubmed/35282442 http://dx.doi.org/10.3389/fendo.2022.838027 |
work_keys_str_mv | AT safirisaeid prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT karamzadnahid prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT kaufmanjays prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT bellariellewilder prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT nejadghaderiseyedaria prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT sullmanmarkjm prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT moradilakehmaziar prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT collinsgary prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 AT kolahialiasghar prevalencedeathsanddisabilityadjustedlifeyearsdalysduetotype2diabetesanditsattributableriskfactorsin204countriesandterritories19902019resultsfromtheglobalburdenofdiseasestudy2019 |